Marta LaganÃ

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/10198456/publications.pdf

Version: 2024-02-01

1040056 888059 23 292 9 17 citations h-index g-index papers 23 23 23 294 docs citations times ranked citing authors all docs

#	Article	IF	CITATIONS
1	S-GRAS score for prognostic classification of adrenocortical carcinoma: an international, multicenter ENSAT study. European Journal of Endocrinology, 2022, 186, 25-36.	3.7	41
2	Immunotherapy failure in adrenocortical cancer: where next?. Endocrine Connections, 2018, 7, E5-E8.	1.9	39
3	Efficacy of the EDP-M Scheme Plus Adjunctive Surgery in the Management of Patients with Advanced Adrenocortical Carcinoma: The Brescia Experience. Cancers, 2020, 12, 941.	3.7	38
4	Activity and safety of temozolomide in advanced adrenocortical carcinoma patients. European Journal of Endocrinology, 2019, 181, 681-689.	3.7	30
5	Treatment With 90Y/177Lu-DOTATOC in Patients With Metastatic Adrenocortical Carcinoma Expressing Somatostatin Receptors. Journal of Clinical Endocrinology and Metabolism, 2020, 105, e1-e5.	3.6	22
6	Cytotoxic Effect of Trabectedin In Human Adrenocortical Carcinoma Cell Lines and Primary Cells. Cancers, 2020, 12, 928.	3.7	16
7	Morbidity and mortality of bone metastases in advanced adrenocortical carcinoma: a multicenter retrospective study. European Journal of Endocrinology, 2019, 180, 311-320.	3.7	16
8	Are we failing in treatment of adrenocortical carcinoma? Lights and shadows of molecular signatures. Current Opinion in Endocrine and Metabolic Research, 2019, 8, 80-87.	1.4	13
9	The long and winding road to effective immunotherapy in patients with adrenocortical carcinoma. Future Oncology, 2020, 16, 3017-3020.	2.4	11
10	High Prevalence and Early Occurrence of Skeletal Complications in EGFR Mutated NSCLC Patients With Bone Metastases. Frontiers in Oncology, 2020, 10, 588862.	2.8	8
11	Ribociclib Cytotoxicity Alone or Combined With Progesterone and/or Mitotane in in Vitro Adrenocortical Carcinoma Cells. Endocrinology, 2022, 163, .	2.8	8
12	Adrenocortical Carcinoma and CT Assessment of Therapy Response: The Value of Combining Multiple Criteria. Cancers, 2020, 12, 1395.	3.7	7
13	Clinical Prognostic Factors in Patients With Metastatic Adrenocortical Carcinoma Treated With Second Line Gemcitabine Plus Capecitabine Chemotherapy. Frontiers in Endocrinology, 2021, 12, 624102.	3 . 5	7
14	Estrogen-Like Effect of Mitotane Explained by Its Agonist Activity on Estrogen Receptor-α. Biomedicines, 2021, 9, 681.	3.2	7
15	Supportive therapies in patients with advanced adrenocortical carcinoma submitted to standard EDP-M regimen. Endocrine, 2022, 77, 438-443.	2.3	7
16	Case Report: Exceptional Response to Second Line Temozolomide Therapy in a Patient With Metastatic Adrenocortical Carcinoma. Frontiers in Endocrinology, 2021, 12, 674039.	3.5	5
17	Different management of adrenocortical carcinoma in children compared to adults: is it time to share guidelines?. Endocrine, 2021, 74, 475-477.	2.3	4
18	Antineoplastic activity of artemisinin in adrenocortical carcinoma. Endocrine, 2019, 66, 425-427.	2.3	3

Marta LaganÃ

#	Article	IF	CITATION
19	Hyperthermic Intraperitoneal Chemotherapy for Primary or Recurrent Adrenocortical Carcinoma. A Single Center Study. Cancers, 2020, 12, 969.	3.7	3
20	Progression of Vertebral Fractures in Patients with Adrenocortical Carcinoma Undergoing Mitotane Therapy. Journal of Clinical Endocrinology and Metabolism, 2022, 107, e2167-e2176.	3.6	3
21	Letter to the Editor From Berruti et al: "Cytoreductive Surgery of the Primary Tumor in Metastatic Adrenocortical Carcinoma: Impact on Patients' Survival― Journal of Clinical Endocrinology and Metabolism, 2022, , .	3.6	2
22	Frequency and outcome of SARS-CoV-2 infection in patients with adrenocortical carcinoma followed at a reference center in Italy. Endocrine, 2021, 72, 20-23.	2.3	1
23	Accurate Triage of Oncological Patients for Safely Continuing Cancer Therapy During the SARS-CoV-2 Pandemic. Frontiers in Oncology, 2021, 11, 707346.	2.8	1